Background-The lymphatic system plays a key role in tissue fluid homeostasis and lymphatic dysfunction caused by genetic defects, or lymphatic vessel obstruction can cause lymphedema, disfiguring tissue swelling often associated with fibrosis and recurrent infections with no available cures to date. In this study, retinoic acids (RAs) were determined to be a potent therapeutic agent that is immediately applicable to reduce secondary lymphedema. Methods and Results-We report that RAs promote proliferation, migration, and tube formation of cultured lymphatic endothelial cells by activating fibroblast growth factor receptor signaling. Moreover, RAs control the expression of cell-cycle checkpoint regulators such as p27 Kip1 , p57 Kip2 , and the aurora kinases through both an Akt-mediated nongenomic action and a transcription-dependent genomic action that is mediated by Prox1, a master regulator of lymphatic development. Moreover, 9-cisRA was found to activate in vivo lymphangiogenesis in animals in mouse trachea, Matrigel plug, and cornea pocket assays. Finally, we demonstrate that 9-cisRA can provide a strong therapeutic efficacy in ameliorating experimental mouse tail lymphedema by enhancing lymphatic vessel regeneration. Conclusion-These in vitro and animal studies demonstrate that 9-cisRA potently activates lymphangiogenesis and promotes lymphatic regeneration in an experimental lymphedema model, presenting it as a promising novel therapeutic agent to treat human lymphedema patients. (Circulation. 2012;125:872-882.)
L ymphatic vessels are essential for tissue fluid homeostasis, lipid absorption, and immune cell transport. The lymphatic system is known to be derived from the blood vascular system. 1 During development, lymphatic endothelial cells (LECs) are differentiated from blood vascular endothelial cells in the cardinal vein, and the newly differentiated LECs migrate out to form the initial lymphatic vessel. 1, 2 The homeodomain transcription factor Prox1 plays an essential role in this LEC differentiation process as the master regulator that suppresses the blood vascular endothelial cell phenotype and induces the fate of LECs. 1 
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Lymphedema, or tissue swelling resulting from abnormal tissue fluid accumulation, can be caused by lymphatic malformation owing to genetic defects or secondary lymphatic obstruction owing to surgery or radiation and presents a considerable physical and social burden because currently no treatment is available. Recently, important progress has been reported in the development of treatments based on mesenchymal stem cells or growth factors coupled with lymph node transplantation. 3, 4 However, extensive studies are required before these experimental therapies can become available to treat human lymphedema patients.
Retinoic acids (RAs) are composed of biologically active metabolites of vitamin A and are involved in a broad range of biological processes in vertebrate development by regulating genes important for cell proliferation, differentiation, apoptosis, and metabolism. 5, 6 RAs have been shown to arrest cell-cycle progression and cell proliferation by upregulating key cell-cycle inhibitors such as p21
Cip1 /CDKN1A, 7 p27 Kip1 / CDKN1B, 8 p16 INK4a /CDKN2A, 9 p14 INK4b /CDKN2B, 10 and p19 INK4D /CDKN2D 11 and thus have been developed as therapeutic agents for various types of diseases, including breast cancer and leukemia. 12 RAs also modulate the interaction of endothelial cells with mural cells by suppression of Tie2 signaling, 13 and RA-deficient mouse embryos display uncontrolled proliferation and decreased maturation of endothelium, resulting in defective vascular remodeling during embryogenesis. 14 In contrast, the proangiogenic effect of RAs has also been documented, and RAs stimulate the transcription and translation of vascular endothelial growth factor (VEGF) in nonendothelial cells. Recently, all-trans RA has been shown to be important in the early steps of lymphatic development during embryogenesis. 15 However, the effect of RAs in postdevelopmental lymphatic regeneration remains to be elucidated.
Here, we report that RAs stimulate proliferation, tube formation, and migration of primary human LECs via the fibroblast growth factor (FGF) signaling pathway. Moreover, 9-cisRA stimulates LEC proliferation by regulating the cellcycle-related target genes p27 kip1 , p57 kip2 , and the aurora kinases through both genomic and nongenomic mechanisms. Consistent with these findings, in this study, various animal models demonstrate that 9-cisRA induces in vivo lymphangiogenesis and provides a therapeutic effect in an experimental lymphedema model. Together, the present findings provide support for the development of 9-cisRA as a therapeutic agent to treat human lymphedema patients.
Methods

Mouse Lymphedema Model
The protocols related to this mouse lymphedema model were approved by the Institutional Animal Care and Use Committee of the University of Southern California. We largely followed the previously established protocol for inducing experimental lymphedema in the tails of mice. 16 Two surgeons performed a total of 3 independent experiments using 2 different mouse strains (C57BL/6J and BALB/c) purchased from The Jackson Laboratory (Bar Harbor, ME). Briefly, under a dissecting microscope, we removed a circumferential 2-mm-wide piece of skin located Ϸ1 cm distal of the tail base and severed the deeper lymphatics running alongside the major blood vessels, paying special attention not to damage blood vessels. From postsurgical day 2, we intraperitoneally injected 100 L Figure 1 . Retinoic acids (RAs) activate proliferation, migration, and tube formation of primary human lymphatic endothelial cells (LECs). A, Activation of LEC proliferation by various RA derivatives. Primary human LECs in a low-serum media (1% FBS) were incubated with 1 mol/L of 9-cisRA, TTNPB, AM580, alltrans RA (ATRA), or vehicle (ethanol; 0.1%) alone (Veh). After 48 hours, the total cell number was estimated and displayed as a percent cell number against the vehicle alone-treated control group. Bars represent the SD of quadruplicates. *PϽ0.001 vs the vehicle alone control. B, Dose-dependent activation of LEC proliferation in a low-serum media (1% FBS) by 9-cisRA compared with PBS or vehicle alone for 48 hours. Bars represent the SD of quadruplicates. *PϽ0.001 vs the vehicle alone control. C, Effect of 9-cisRA on the migration of primary LECs. Monolayers of LECs were pretreated with vehicle alone or vehicle containing 9-cisRA (1 mol/L) and scratched with a pipette tip to make a wound. After 24 hours, the total remaining wounded area was determined by image analysis and expressed as a percentage of the total wounded area in the box-and-whisker plot. *PϽ0.05. D, Effect of 9-cisRA on tube formation of primary LECs. Cells were pretreated with vehicle alone or vehicle with 9-cisRA (1 mol/L) for 24 hours, and an equal number of cells were seeded onto the growth factor-depleted Matrigel. After 24 hours, 5 representative images were taken, and the total tube length per image was calculated and charted as a percentage of the vehicle-treated group. *PϽ0.05.
vehicle (10 L of 100% ethanol and 90 L sunflower seed oil; Sigma Aldrich) into the control mouse group or 100 L vehicle solution containing 9-cisRA (0.08 mg/kg) daily. The diameter of the proximal and distal sides of the surgical site in the tail was measured every other day. At the end of the experiments, mouse tails were surgically removed and processed for further immunohistochemical analyses.
Supplemental Methods
Detailed information on the cell culture reagents and assays for cell proliferation, migration, tube formation, immunofluorescence, gene expression, luciferase, chromatin immunoprecipitation, corneal pocket assay, mouse trachea, and Matrigel plug is available in the online-only Data Supplement.
Statistical Analysis
The outcome measures are expressed as the meanϮSD per experimental condition unless noted otherwise. ANOVA was used to detect differences in outcome measures across the experimental and control groups for all in vitro and in vivo experiments. Pairwise comparisons of least-squares means between groups were adjusted by use of the Dunnett or Tukey test whenever appropriate. A mixed linear model with the autoregressive covariance structure over time was used to compare tail diameters over time by treatment and side of wounds. Analyses were performed with the SAS statistical package version 9.2 (SAS Institute Inc, Cary, NC). All reported P values were 2 sided at a significance level of 0.05.
Results
RAs Promote the Proliferation, Migration, and Tube Formation of Primary Human LECs
We investigated the effect of RAs on LEC proliferation using various RA derivatives such as 9-cisRA, all-trans RA, TT-NPB (pan-RA receptor ligand), and AM580 (RAR-␣-specific ligand) 17 and found that all of these RA derivatives enhanced the proliferation of primary LECs ( Figure 1A) . We then chose 9-cisRA, which has been approved by the Food and Drug Administration to treat Kaposi sarcoma, an endothelial tumor with a lymphatic endothelial phenotype, and found that it promotes LEC proliferation in a dose-dependent manner ( Figure 1B ). The effect of 9-cisRA on LEC migration was also studied by scratch assays on LECs that had been pretreated with either vehicle or 9-cisRA. At 24 hours, the scratched area was fully recovered in the 9-cisRA-treated LECs but not in the vehicle-treated control LECs ( Figure 1C ), indicating that 9-cisRA treatment significantly promoted the migration of primary LECs. Assays using the modified Boyden chamber that evaluates the directional migratory activity of LECs by 9-cisRA yielded results that are consistent with this finding ( Figure 2D ). In addition, 9-cisRA enhanced the tube-forming capability of LECs on the surface of Matrigel ( Figure 1D ). Taken together, these in vitro studies demonstrate that 9-cisRA significantly activates the proliferation, migration, and tube formation of cultured primary human dermal LECs.
FGF Signaling Plays a Key Role in 9-cisRA-Induced LEC Proliferation and Migration
We then set out to define the mechanism for the 9-cisRAinduced mitogenic and migration activities of LECs. Because VEGF and FGF are among the best-characterized cytokines that activate proliferation of LECs, 18 -22 we investigated whether either or both of the 2 signaling pathways were involved in 9-cisRA-induced LEC proliferation by using specific inhibitors for each pathway. Primary LECs were incubated with chemical inhibitors against FGF receptors (FGFRs), 23 VEGF receptor (VEGFR)-2, 24 and VEGFR-3 25 before 9-cisRA treatment. Interestingly, although the FGFR inhibitor resulted in a significant suppression of the 9-cisRAinduced LEC proliferation (Figure 2A ), neither the VEGFR-2 nor VEGFR-3 inhibitor exhibited any suppression ( Figure  2A ). This finding prompted us to further evaluate the expression of FGFRs in LECs on 9-cisRA treatment. Semiquantitative reverse-transcriptase polymerase chain reaction analyses revealed that the expression of FGFR-1 was largely unchanged and FGFR-2 was not detected in LECs ( Figure  2B ). In comparison, FGFR-3 and FGFR-4 were transiently upregulated by Ϸ8-and Ϸ2-fold, respectively, at 6 hours after 9-cisRA treatment ( Figure 2B ). We have previously reported that FGFR-3 is prominently expressed in LECs over blood vessel endothelial cells and plays an important role in FGF signaling in LECs. 26 To define the essential role of FGFR-3 in the 9-cisRA-induced activation of LEC proliferation, primary LECs were preincubated with a soluble recombinant FGFR-3 protein before 9-cisRA treatment. Indeed, soluble FGFR-3 recombinant protein significantly suppressed the 9-cisRA-activated LEC proliferation ( Figure 2C ), suggesting that soluble FGFR-3 protein sequesters FGF ligands that mediate 9-cisRA-induced LEC proliferation. Consistent with this, the FGFR inhibitor suppressed the 9-cisRAinduced migratory activity of LECs based on a directional migration assay using a modified Boyden chamber ( Figure  2D ). Together, these data indicate that FGF/FGFR signaling contributes significantly to the 9-cisRA-induced proliferation and migration of primary LECs. 27 and neuronal cells, 10 through an upregulation of cyclin-dependent kinase (CDK) inhibitors, we studied the 9-cisRA regulation of various cell-cycle regulators in LECs. In contrast to previous studies, 2 major CDK inhibitors, p27
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Kip1 (CDKN1B) and p57 Kip2 (CDKN1C), were strongly downregulated in 9-cisRA-treated LECs as shown by real-time reverse-transcriptase polymerase chain reaction, Western blot, and immunofluorescence studies (Figure 3A-3D ). Importantly, it has been reported that p27 Kip1 and p57
Kip2 function as key cell-cycle brakes and that their inhibition is sufficient to induce the cells to enter the S phase of the cell cycle. 28 In addition, Western blot analyses revealed that 9-cisRA treatment induced the expression of the aurora kinases A and B, which play an important role in the G2/M phase of cell-cycle progression 29 ( Figure 3E ). Taken together, these data demonstrate that 9-cisRA controls the expression of 2 major CDK inhibitors (p27 Kip1 and p57 Kip2 ) and 2 aurora kinases (AURKA and AURKB), which have critical functions in the G1/S and G2/M transition in LECs, respectively.
Genomic and Nongenomic Mechanisms for the 9-cisRA-Mediated Regulation of p27
Kip1
, p57 Kip2 
, and the Aurora Kinases in LECs
It is known that RAs exert their functions through 2 modes of action; a conventional, genomic mechanism that relies on nuclear hormone receptor-mediated transcription and a more rapid form of nongenomic action that does not require gene transcription. 12 Recent studies have identified a novel, nongenomic effect of RAs in cell-cycle regulation through PI3 kinase. 12 We thus investigated the possibility of p27 Kip1 downregulation by the PI3K/Akt pathway resulting from 9-cisRA because Akt activation is the major signal for downregulation of p27
Kip1 but not p57 Kip2 . 30 Indeed, we detected rapid phosphorylation of Akt by 9-cisRA within 10 minutes, whereas vehicle treatment did not show any sign of Akt activation ( Figure 4A ). Moreover, we found that, from the first hour of 9-cisRA treatment, p27
Kip1 became phosphorylated at its serine 10 residue ( Figure 4B ), which is known to be important for the degradation of protein. 31 Consistent with this, pretreatment of LECs with an Akt inhibitor (LY294002) effectively blocked the 9-cisRA-induced LEC proliferation and migration ( Figure 4C and 4D) . These data indicate that Akt-mediated p27
Kip1 downregulation and phosphorylation may play a key role in the 9-cisRAinduced nongenomic effect on LEC proliferation and migration.
On the other hand, the expression of p57 Kip2 has been shown to be regulated by Prox1, the master regulator for lymphatic development. 32 In support of this, when we inhibited the expression of Prox1 with a small interfering RNA (siRNA) in primary LECs, only p57 Kip2 , not p27 Kip1 , was significantly downregulated ( Figure 4E ). Moreover, when Prox1 was overexpressed by adenovirus in human umbilical venous endothelial cells, a cell type that does not express the lymphatic marker Prox1, p57
Kip2 , but not p27 Kip1 , was significantly upregulated ( Figure 4F ). Importantly, chromatin immunoprecipitation assay revealed that Prox1 was physically associated with the p57
Kip2 promoter ( Figure 4G ). We performed p57
Kip2 promoter-reporter assays and found that Prox1 strongly activated the p57
Kip2 promoter ( Figure 4H ). These data indicate that the Prox1 protein binds to the p57 Kip2 promoter and directly activates its transcription in LECs. Notably, Western blot studies revealed that the expression of the p57
Kip2 protein was strongly downregulated within the first 1 to 2 hours of 9-cisRA treatment ( Figure 3C ). Chromatin immunoprecipitation assay revealed that although the Prox1 protein bound to the p57
Kip2 promoter in the vehicletreated LECs, 9-cisRA treatment induced a rapid dissociation of the Prox1 protein from the p57
Kip2 promoter within 0.5 hours without affecting the Prox1 protein expression level ( Figure 4I ). This finding indicates that 9-cisRA treatment immediately decreased the DNA-binding affinity of Prox1 toward the p57 Kip2 promoter. Moreover, because Prox1 overexpression induced p57
Kip2 expression in the absence of 9-cisRA but did not induce it in the presence of 9-cisRA ( Figure 4J ), we conclude that 9-cisRA regulates p57 Kip2 expression predominantly by modulating Prox1 binding to its promoter in LECs. Taken together, these data demonstrate that 9-cisRA inhibits Prox1 binding to the p57
Kip2 promoter and thus downregulates p57 Kip2 , resulting in the cell-cycle progression of LECs.
We searched for additional cell cycle-related genes regulated by Prox1 and studied the transcriptional profiles of various cell cycle-related genes after Prox1 knockdown in LECs. Although knockdown of Prox1 alone yielded only Figure 4 (Continued). (ϩϩ)] for 30 minutes before 9-cisRA treatment (1 mol/L) and allowed to grow for 48 hours before determination of the relative cell numbers. Note that the inhibition of the PI3K/Akt signal blocked 9-cisRA-induced LEC proliferation. D, Similarly, LECs were pretreated with LY294002 [100 nmol/L (ϩϩ)] for 30 minutes before 9-cisRA treatment (1 mol/L) and allowed to migrate in the modified Boyden chamber for 3 hours before measurement of the relative number of migrated cells. Note the essential role of the Akt-mediated nongenomic action of 9-cisRA in LEC migration. E, Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) assays showed that knockdown of Prox1 in LECs resulted in downregulation of p57
Kip2 but not p27 Kip1 . F, Adenoviral overexpression of Prox1 (AdProx1) in human umbilical vein endothelial cells for 48 hours strongly induced p57
Kip2 , but not p27 Kip1 , as determined by qRT-PCR. AdCTR indicates control adenovirus. G, Chromatin immunoprecipitation (ChIP) assays for Prox1 in LECs performed against the p57 Kip2 promoter using 2 independent PCR primer sets showed a physical association of the Prox1 protein with the p57 Kip2 promoter. H, Luciferase-reporter assays measuring the response of the different-length proximal promoters of p57 Kip2 to Prox1-mediated activation. The reporter constructs were named by the position of the 5Ј and 3Ј ends of the promoter fragments relative to the transcriptional start site (ϩ1) of p57 Kip2 . I, Prox1 ChIP was performed against the p57 Kip2 promoter from LECs treated with vehicle (Veh) or 9-cisRA (1 mol/L) for 0.5 or 4 hours. The expression level of Prox1 protein was also determined in LECs treated with 9-cisRA for 2 hours. J, Western blot assay showing that overexpression of Prox1 in the presence of 9-cisRA did not induce the expression of p57 Kip2 . K, Prox1 ChIP revealed that, on treatment of LECs with 9-cisRA (1 mol/L for 4 hours), Prox1 dissociated from the promoters of the aurora kinases A (AURKA) and B (AURKB) and survivin. Prox1 did not bind to the promoters of CCNB1 and CCNB2. For C, D, through F and H, data are shown as meanϮSD. *PϽ0.05. moderate changes in cell-cycle genes, simultaneous knockdown of both Prox1 and retinoid X receptor-␣, a nuclear receptor of 9-cisRA, synergistically upregulated several important cell-cycle-related genes such as the aurora kinases A and B, survivin, cyclin B1 and B2, KI67 nuclear antigen, and the NEK2 and PBK kinases (Table) , indicating that Prox1 and retinoid X receptor-␣ may cooperatively repress the expression of these cell-cycle-related genes. Moreover, chromatin immunoprecipitation studies showed that Prox1 also binds to the promoters of aurora kinases A/B and survivin and that treatment of 9-cisRA caused a rapid dissociation of Prox1 from the promoters within 4 hours ( Figure 4K ). Taken together, these studies demonstrate that 9-cisRA activates cell-cycle progression through both genomic and nongenomic actions and that Prox1, the master regulator for lymphatic differentiation, is intricately involved in the genomic effect of 9-cisRA on cell-cycle progression.
9-cisRA Enhances In Vivo Lymphangiogenesis
To extend the in vitro findings, we set out to evaluate the prolymphangiogenic potential of 9-cisRA and performed various in vivo lymphangiogenesis assays using the mouse trachea, Matrigel plugs, and cornea. For the mouse trachea assay, vehicle solution with or without 9-cisRA was dropped into mouse nostrils daily, and trachea specimens were collected after 5 days and stained for the lymphatic vessel marker LYVE-1 ( Figure 5A-5E ). We found that, compared with the vehicle control, 9-cisRA significantly activated lymphangiogenesis, determined by the total length of the capillary lymphatic vessels on the luminal side of the trachealis muscle, where lymphatic vessels are otherwise only sparsely present ( Figure 5A versus 5B). Moreover, whereas the vehicle-treated lymphatic vessels were round ended, 9-cisRA-treated lymphatic vessels displayed lymphatic in C) , whereas the lymphatics in the 9-cisRA-treated trachea have jagged ends (arrows in D), indicating active lymphatic sprouting. E, Total length of the lymphatic vessels was measured on the luminal side of the trachealis muscle, which is largely devoid of lymphatic vessels. F through H, Mouse subcutaneous Matrigel plug assay. Matrigel premixed with vehicle alone (F) or 9-cisRA (10 mol/L) (G) was subcutaneously injected (2 Matrigel plugs per mouse, 5 mice each group) and harvested after 2 weeks for immunohistochemistry (IHC) analyses with an anti-podoplanin antibody. The relative lymphatic vessel area was determined in the Matrigel with NIH ImageJ software (H). Bar (G)ϭ50 m. I through K, 9-cisRA stimulates lymphangiogenesis in the mouse cornea. Representative LYVE-1 (red) immunofluorescent images are shown to demonstrate lymphatic vessel ingrowth into the cornea implanted with a vehicle pellet (I) or a 9-cisRA pellet (J) after 14 days. Dotted line is the demarcation between the cornea and conjunctiva. Original magnification ϫ100. K, A significant difference was observed in the lymphatic coverage area between the vehicle (10 mice) and 9-cisRA (13 mice) groups. Error bars represent SEM. L and M, Subcutaneous Matrigel plug assay using the previously reported lymphatic-specific green fluorescent protein (GFP) mice 32 to visualize the newly formed lymphatic networks. Matrigel premixed with vehicle alone (L) or vehicle containing 9-cisRA (10 mol/L) (M) was injected into the skin of the lymphatic-specific GFP mice (2 Matrigel plugs per mouse, 5 mice each group) and isolated after 2 weeks. Lymphatic vessels within the Matrigels were directly visualized under a fluorescent stereoscope. Figure 6 . Therapeutic effect of 9-cis retinoic acid (RA) on secondary lymphedema and lymphatic vessel regeneration. Experimental lymphedema was surgically induced in the tail of C57BL/6J mice, and vehicle alone (ethanol/seed oil) or vehicle with 9-cisRA (0.08 mg/kg) was injected intraperitoneally daily from day 2. Images of secondary lymphedema development in female (A-C) and male (D-F) mice treated with vehicle (Veh) or 9-cisRA (9cRA) for 32 days. The diameter of the tail on the distal (white arrowheads) and proximal sides of the wounds was measured every other day and charted for the female (B) and male (E) mice. Six females and 5 males were used for the vehicle-treated group, and 7 females and 6 males were used for the 9-cisRA-treated group. †PϽ0.05; *PϽ0.01. C and F, tipped cells with jagged filopodia (Figure 5C versus 5D ). This assay indicates that 9-cisRA activated lymphatic vessels to sprout and then invade the stroma of the trachea, a typical feature of active lymphangiogenesis.
We also performed a Matrigel plug assay by subcutaneously implanting growth factor-depleted Matrigel that had been premixed with vehicle or 9-cisRA. After 2 weeks, Matrigel plugs were harvested, embedded in paraffin, and analyzed for lymphatic capillaries with an anti-podoplanin antibody ( Figure 5F versus 5G) . We found that the 9-cisRAcontaining Matrigel plugs recruited roughly 2-fold more podoplanin-positive lymphatic vessels than vehicle-alone Matrigel plugs. Moreover, activation of lymphangiogenesis by 9-cisRA was also assessed by mouse cornea micropocket assay. A slow-release pellet containing vehicle or 9-cisRA was implanted into the cornea, and newly formed lymphatic vessels were quantified after 14 days by LYVE-1 staining ( Figure 5I versus 5J ). This assay demonstrates that 9-cisRA induced 4 times more lymphatic vessel growth than vehicle alone. In addition, we used the lymphatic-specific green fluorescent protein (GFP) transgenic (Prox1-GFP) mice that we recently reported 33 to directly visualize the macroscopic view of lymphatic ingrowth into Matrigel implants containing 9-cisRA. Consistent with the results from the above assays, 9-cisRA stimulated a significantly higher lymphangiogenic activity than vehicle alone in Matrigel implants ( Figure 5L versus 5M). Together, the trachea, Matrigel plug, and cornea micropocket assays consistently demonstrate that 9-cisRA can strongly activate in vivo lymphangiogenesis.
Therapeutic Efficacy of 9-cisRA in Experimental Mouse Tail Lymphedema
We next investigated the therapeutic effect of 9-cisRA by using the mouse tail lymphedema model that has been used as a model of human secondary lymphedema. 16 We induced experimental lymphedema by surgically obstructing the dermal and deep lymphatic vessels in both female and male mouse tails and daily intraperitoneally administered 9-cisRA or vehicle alone starting from postprocedural day 2. For 3 to 4 weeks, we measured the diameters of the tails on the proximal and distal sides of the incisions. Lymphedema was induced in 2 mouse strains, C57BL/6J ( Figure 6 ) and BALB/c ( Figure I in the online-only Data Supplement), by 2 different researchers, and the outcome was consistent. From both mouse strains, we observed that 9-cisRA treatment significantly reduced the secondary tail lymphedema. Specifically, in female mice of both strains, lymphedema had similarly developed in the vehicle-and 9-cisRA-treated groups in the first week after surgery. However, the lymphedema in the vehicle-treated mice developed continuously in the second week and reached a peak in the third week before tapering off in the fourth week ( Figure 6A and 6B) . In a clear comparison, the lymphedema of the 9-cisRA-treated mice began to resolve during the second week and returned largely to the baseline level at the end of the fourth week, demonstrating a potent therapeutic effect of 9-cisRA in this mouse experimental lymphedema model. In male mice of both strains, however, whereas the lymphedema in the vehicle-treated male mice peaked during the first week and was maintained throughout the second half of the experiment, the 9-cisRA treatment clearly decreased the formation of the lymphedema and accelerated the resolution of the tissue swelling in the tail ( Figure 6D and 6E) . This distinct pattern of lymphedema formation and resolution between the sexes and the therapeutic effect of 9-cisRA were also detected in BALB/c mice ( Figure I in the online-only Data Supplement). We then harvested the tails from the 2 groups and performed immunohistochemical analyses of the lymphatic vessels ( Figure 6C and 6F). Importantly, lymphatic regeneration was much more prominent in the 9-cisRA-treated group than in the vehicletreated group, indicating that the 9-cisRA-promoted amelioration of lymphedema is associated with increased lymphatic regeneration. Quantitative analyses of the lymphatic vessels are shown in Figure VI in the online-only Data Supplement. To investigate whether 9-cisRA promotes skin wound healing, which may help to indirectly resolve the lymphedema, we evaluated the effect of 9-cisRA on wound healing in the skin and found that daily intraperitoneal treatment of 9-cisRA did not accelerate or promote wound healing ( Figure II in the online-only Data Supplement). Taken together, these findings demonstrate that 9-cisRA effectively promotes lymphatic regeneration in experimental mouse lymphedema model and is clinically applicable to the treatment of postsurgical lymphedema in humans.
Discussion
RAs have been shown to induce cell-cycle arrest in various cell types and are in clinical use as therapeutic agents. 12 In particular, 9-cisRA has been shown to have an antiangiogenic effect and received Food and Drug Administration approval for the topical treatment of cutaneous lesions of Kaposi sarcoma, an endothelial cancer. 12 Unexpectedly, however, our initial study to understand the effect of RAs on the function of Prox1 in human primary LECs led us to fortuitously uncover a previously unidentified role of RAs in postdevelopmental lymphatic regeneration. Subsequent investigation revealed that RAs can potently induce lymphangiogenesis in vitro and in vivo and demonstrated therapeutic efficacy in an experimental lymphedema model. Consistent with this, these findings are supported by a recent study showing that all-trans RA promotes the early steps of lymphatic differentiation and development. 15 In strong agreement, we found that all-trans RA potently induced LEC proliferation in vitro ( Figure 1 ) and lymphatic vessel growth in the mouse cornea and Matrigel plug assays ( Figure III in the online-only Data Supplement). In contrast, 9-cisRA nei- Figure 6 (Continued). After 32 days, prominent regeneration of LYVE-1-positive lymphatic vessels was detected in the 9-cisRA-treated mice compared with the vehicle-treated group in both sexes. For statistical analyses, a mixed linear model with the autoregressive covariance structure over time was used to compare tail diameters over time by treatment and distal side of the wounds. A statistically significant difference (PϽ0.001) was observed for the distal side of the wounds in females from days 12 to 32 and in males from days 6 to 32. No statistical difference was found for the proximal side of the wounds between the 2 groups in both sexes. Similar data were obtained from an experiment using BALB/c mice ( Figure I in the online-only Data Supplement).
ther activated proliferation of human dermal blood vascular endothelial cells ( Figure IV in the online-only Data Supplement) nor promoted blood vessel growth when implanted in the mouse cornea (data not shown). Because 9-cisRA and all-trans RA can bind and activate both retinoid X receptor and RA receptor, 5 we hypothesize that the lymphangiogenic activity of RA may be mediated by either or both of these RA nuclear receptors and perhaps also by other RA-binding proteins such as RBP, CRBP, and CRABP.
In this study, we dissected the molecular mechanisms underlying the prolymphangiogenic effect of 9-cisRA and found that 9-cisRA exerts its effects through both genomic and nongenomic actions. The transcription-dependent genomic action of 9-cisRA was found to be mediated through the regulation of PROX1 gene expression and Prox1 protein activity. The data clearly showed that 9-cisRA rapidly dissociates the Prox1 protein from the promoter of the cell-cycle inhibitor p57 Kip2 , which leads to the downregulation of p57 Kip2 . 9-cisRA was also found to upregulate the aurora kinases A and B, serine/threonine kinases essential for cell-cycle progression through the G2/M phase, by a genomic effect that involves the dissociation of the Prox1 protein from the promoter. Moreover, siRNA-mediated knockdown of Prox1 and retinoid X receptor-␣ in LECs resulted in a cooperative upregulation of multiple cell-cycle-regulated genes. Therefore, Prox1 plays a key role in mediating the genomic action of 9-cisRA so as to stimulate LEC proliferation. On the other hand, the downregulation and phosphorylation of p27
Kip1 by 9-cisRA indicate that the nongenomic effect of 9-cisRA for LEC proliferation may be mediated by Akt activation because Akt activation is the major signal for repressing the expression of p27 Kip1 . 30 The blocking of Akt activation prevented 9-cisRA-induced LEC proliferation and migration ( Figure 4C and 4D ). Interestingly, the mRNA level of another cell cycle regulator, p21
Cip1 , was found to be transiently increased by 9-cisRA treatment (Figure V in the online-only Data Supplement). Taken together, we conclude that enhanced LEC proliferation and migration by 9-cisRA is a combined outcome of both genomic and nongenomic actions.
To the best of our knowledge, this is the first report of both the effects of 9-cisRA on lymphangiogenesis and its therapeutic efficacy in secondary lymphedema. Although several prolymphangiogenic factors have previously been implicated in the treatment of lymphedema, 34 9-cisRA is a metabolite of vitamin A that has been characterized extensively for its biochemical, physiological, pharmacological, and toxicological properties and thus can be used immediately to treat human patients. In fact, 9-cisRA and other RAs are already being prescribed for various human diseases. Therefore, the present study identifies 9-cisRA as one of the most promising therapeutic agents against human lymphedema, a disease without any currently available effective treatment.
Conclusions
We have shown 9-cisRA to be a potent lymphangiogenic factor that stimulates the proliferation, migration, and tube formation of cultured LECs and lymphatic vessel growth in various animal models. Furthermore, 9-cisRA treatment significantly accelerated the resolution of surgically induced mouse tail lymphedema. Therefore, this evidence provides strong support for further development of 9-cisRA as a therapeutic agent to treat human lymphedema.
